Central precocious puberty (CPP) and early puberty (EP) may be associated with an increased body mass index (BMI), adiposity, and with an increased prevalence of obesity before, during and after discontinuing GnRH analog (GnRHa) treatment when compared with age- and sex-matched reference values of the same population[1-4]. Here, GNRH1 is linked to central precocious puberty.